ABIONYX Pharma Announces Its 2023 Half-Year Financial Results
26 Septembre 2023 - 8:00PM
Business Wire
Regulatory News:
ABIONYX Pharma, (FR0012616852 - ABNX - PEA PME eligible),
a new generation biotech company dedicated to the discovery and
development of innovative therapies based on the world's only
recombinant apoA-1, today announces its financial results for the
first half of 2023.
Selected financial information (as of June 30,
2023/Consolidated financial statements under IFRS)
€m
H1 2023
H1 2022
Revenues
2.13
2.63
Cost of goods and services sold
(2.14)
(2.54)
R&D expenditure
(0.76)
(0.70)
Administrative and commercial expenses
(1.46)
(1.85)
Operating Income
(2.23)
(2.46)
Financial income
0.10
0.10
Financial expenses
(0.12)
(0.19)
Financial result
(0.02)
(0.09)
Net income
(2.25)
(2.55)
€m
H1 2023
2022
Net cash flow from operating
activities
(2.54)
(3.36)
Net cash used in investing activities
(0.07)
(0.18)
Net cash flow from financing
activities
0.49
(0.19)
Change in cash and cash
equivalents
(2.12)
(3.73)
Cash and cash equivalents at end of
year
1.93
4.04
Details of the main changes in the consolidated financial
statements
The Group recorded consolidated half-year revenues of €2,128K, a
decrease compared with June 30, 2022. As a reminder, IRIS Pharma is
the only Group entity to generate revenues by June 30, 2023.
ABIONYX Pharma did not generate any revenues in the first half of
the year in its business dedicated to the discovery and development
of innovative therapies designed to improve patients' lives. Since
the integration of IRIS Pharma, the Group the Group has focused on
preclinical studies of bio-HDL as part of its clinical development
in ophthalmology.
Research and development expenditures amounted to €759K as of
June 30, 2023, compared with €704 K as of June 30, 2022. Since the
beginning of the year, the Company successfully completed its first
two batches for the industrial GMP (Good Manufacturing Practice)
biomanufacturing of CER-001 using an innovative and robust
method.
Administrative and commercial expenses amounted to €1,464K as of
June 30, 2023, compared with €1,856K as of June 30, 2022.
After taking these expenses into account, the operating income
went from a loss of €2,455K as of June 30, 2022, to a loss of
€2,228K as of June 30, 2023.
The financial result shows a deficit of €20K as of June 30,
2023, compared to a deficit of €95K in the first half of 2022. The
financial result is mainly due to losses on the purchase of own
shares under the liquidity contract, losses on the payment of
foreign currency trade payables (mainly in USD and GBP), interest
charges on loans from credit institutions, as well as financial
charges recognized in the context of the application of IFRS 16 on
leases.
The net loss amounts to €2,248K as of June 30, 2023, compared to
a loss of €2,550K as of June 30, 2022.
Cash and cash equivalents, before collection of the 2022 French
Research Tax Credit (CIR), amounted to €1.9 million as of June 30,
2023, compared with €4,0 million as of December 31, 2022. CIR
receivables for 2022, that had not yet been reimbursed as of June
30, 2023, represent a total amount of €1,455K.
To support the biomanufacturing of CER-001, the Company decided
to set up an equity-linked financing facility to secure a maximum
investment of €12 million over the next two years.
2023 outlook
The Company looks forward to the publication in a scientific
journal by the end of 2023 of the detailed clinical results of the
RACERS study, notably concerning the reduction in the number of
days spent in intensive care units for patients treated with the
biologic CER-001, and the improvement in 30-day survival.
The Half-Year financial report as of June 30, 2023 has been
made available to the public and published on the website of the
Autorité des Marchés Financiers (AMF).
About ABIONYX Pharma
ABIONYX Pharma is a new generation biotech company that aims to
contribute to health through innovative therapies in indications
where there is no effective or existing treatment, even the rarest
ones. Thanks to its partners in research, medicine,
biopharmaceuticals and shareholding, the company innovates on a
daily basis to propose drugs for the treatment of renal and
ophthalmological diseases, or new HDL vectors used for targeted
drug delivery.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230926302731/en/
NewCap Investor relations Nicolas Fossiez Louis-Victor
Delouvrier abionyx@newcap.eu +33 (0)1 44 71 98 53
NewCap Media relations Arthur Rouillé abionyx@newcap.eu
+33 (0)1 44 71 00 15
Abionyx Pharma (EU:ABNX)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Abionyx Pharma (EU:ABNX)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024